More Good News Showing
Embryonic Stem Cells Not Needed
Readers with memories far
superior to mine may recall that a little over a year ago I
wrote about the breathtaking work of Dr. Denise Faustman. At the
time I explained about how the Lee Iacocca Foundation was
raising money to support Dr. Faustman "whose research team in
2003 not only reversed, but actually cured Type I diabetes in
mice. This is of particular interest to pro-lifers because her
work is proving yet again that there is no need to lethally
scavenge stem cells from human embryos to treat diseases."
Well, just last week three
articles appeared in the Journal Science that confirmed the key
findings of Dr. Faustman's research. And do ironies abound.
According to the Wall
Street Journal's Sharon Begley, an author of one of the three
confirmatory studies had co-written an extremely critical letter
two years ago sent (but never published) to the New York Times.
(The Times had run an article about Dr. Faustman's work written
by reporter Gina Kolata.) Among other things, the letter,
written by two fellow Harvard diabetes experts, described as
"patently false" Dr. Faustman's assertion that she was the first
scientist to cure diabetes in mice.
My, my, how times change.
Kolata's March 24, 2006, story begins this way.
"Three groups of
scientists report today that they independently replicated a
controversial finding: severely diabetic mice can recover on
their own if researchers squelch an immune system attack that is
causing the disease.
"It is a discovery that
was first published in 2001 and raised the hopes of people with
Type 1 diabetes, which usually occurs in puberty and afflicts an
estimated half-million to a million Americans. If the findings
applied to humans, they might mean reversing a disease that had
seemed incurable.
"The findings also gave
rise to questions about using embryonic stem cells as
replacement cells for diabetics, a method that is the focus of
intense interest. If it is possible, in mice, for the pancreas
to cure itself, and if the same finding holds true in humans -
which, so far, is entirely unknown - adding embryonic stem cells
as the source of new pancreas cells might provide little added
benefit, if any."
In Type I diabetes the
immune system attacks the insulin-secreting beta cells which
reside in the pancreas. Insufficient insulin means blood sugar
is not kept in check. This can lead to kidney failure,
blindness, and amputations.
All three studies followed
the formula outlined by Dr. Faustman in her paper reported in
Science in 2003.
A mixture of "water, oil
and parts of dead bacteria" was injected into diabetic mice.
This "overstimulates the immune system cells that are attacking
the pancreas, making those white blood cells self-destruct,
effectively stopping the attack and allowing the pancreas to
cure itself," according to Kolata.
Begley described it
differently. The researchers from the University of Chicago,
Harvard, and Washington University in St. Louis induced "beta
cells in some (but not all) of the animals essentially to come
back from the dead, curing their diabetes."
In her work Dr. Faustman
also reported that cells transplanted from the spleens of
healthy mice differentiated into insulin-secreting beta cells in
diabetic mice. This could boost the response in mice, she wrote.
The three new studies were
unable to replicate that portion of her work. "Denise Faustman
was extremely helpful to us in duplicating her protocol, but
it's possible we did something wrong, and so can't absolutely
rule out the possibility that the spleen contains stem cells
that can become beta cells," Chicago's Louis Philipson told
Kolata. (It was the suggestion that adult stem cells residing in
the spleen could "morph into specialized cells," Begley wrote,
that "land[ed] her smack in the middle
of the stem-cell debate." A number of scientists are heavily
invested in harvesting stem cells from human embryos. Any
suggestion that killing human embryos for their stem cells might
not be necessary poses a direct
threat.)
However, the studies all
demonstrated that just stopping the immune system's assault was
enough to cure the mice. The point, as one researcher told
Kolata, was "that the pancreas cells came back on their own."
Speaking of Lee Iacocca,
according to Kolata, he has raised $11 million for studies to
test Dr. Faustman's initial discoveries, including clinical
trials lead by Harvard's David Nathan. "Patients clamored to be
included," Kolata wrote. "Even though she is not ready to begin
even the most preliminary tests, she already has 600 on a
waiting list."
Please send your comments
to Dave Andrusko at
dandrusko@nrlc.org.